Crossmark

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Crossref DOI link: https://doi.org/10.1053/j.ajkd.2019.06.009

Published Print: 2020-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Levey, Andrew S.

Gansevoort, Ron T.

Coresh, Josef

Inker, Lesley A.

Heerspink, Hiddo L.

Grams, Morgan E.

Greene, Tom

Tighiouart, Hocine

Matsushita, Kunihiro

Ballew, Shoshana H.

Sang, Yingying

Vonesh, Edward

Ying, Jian

Manley, Tom

de Zeeuw, Dick

Eckardt, Kai-Uwe

Levin, Adeera

Perkovic, Vlado

Zhang, Luxia

Willis, Kerry
Funding

Funding for this research was provided by:

Alexion

Astellas

AstraZeneca

Bayer

Boehringer-Ingelheim

Gilead

Ironwood

Kyowa Hakko Kirin

Merck

Novartis

Novo-Nordisk

National Institutes of Health

Siemens

NIH

NKF

Tufts Medical Center

Abbvie

AstraZeneca

Boehringer Ingelheim

Gilead

Merck (all

NKF

NKF

Abbvie

Boehringer Ingelheim

GSK

Novo Nordisk

Abbvie

Bayer

Ipsen

Sanofi-Genzyme
License Information

Text and Data Mining valid from 2020-01-01

Text and Data Mining valid from 2020-01-01
More Information

This article is maintained by: Elsevier

Article Title: Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Journal Title: American Journal of Kidney Diseases

CrossRef DOI link to publisher maintained version: https://doi.org/10.1053/j.ajkd.2019.06.009

Content Type: article

Copyright: © 2019 by the National Kidney Foundation, Inc.

Document is current

Any future updates will be listed below